Treatment of pseudobulbar affect in a mixed neurodegenerative disorder with compounded quinidine capsules and dextromethorphan cough syrup

Yannick Villeneuve1, Diana Cruz-Santiago2,3, Helene Masson4 and Doris Clerc5

Abstract
An elderly woman admitted in our geriatric inpatient unit suffered from disturbing outbursts of crying and, less frequently, episodes of laughing. The patient was diagnosed with pseudobulbar affect related to a mixed neurodegenerative disorder. This condition is often underdiagnosed and undertreated, despite being relatively frequent in patients with neurodegenerative disorders. This case report describes the treatment of pseudobulbar affect in this patient. The only available treatment in Canada for this condition, antidepressants, was not effective for our patient. Dextromethorphan/quinidine is a good accepted alternative, but the combination is not marketed in Canada. To manage this problem, we used compounded quinidine capsules and dextromethorphan cough syrup. The crying of our patient improved significantly and rapidly after the initiation of this treatment. This case will help professionals to review their central role in treating this complex and disabling condition.

Keywords
Pseudobulbar affect, crying, laughing, neurodegenerative disorder, geriatrics, compounded quinidine capsules, dextromethorphan cough syrup, alternative Nuedexta®

Date received: 31 August 2019; accepted: 27 March 2020

Introduction
Pseudobulbar affect (PBA) is a condition associated with excessive crying or laughing in situations that would normally not trigger this type of reaction. The reaction is either disproportionate or incongruent to the situation.1-3 This condition is relatively frequent in neurological disorders,4 but, according to a panel consensus, it is often underdiagnosed and undertreated.5 PBA can also be misdiagnosed with a psychiatric condition because of the presentation.6 One accepted treatment of PBA, dextromethorphan/quinidine (DM/Q) combination, is not available in Canada. This case report describes the treatment with compounded quinidine capsules and dextromethorphan cough syrup in a patient diagnosed with PBA related to a mixed neurodegenerative disorder. The role of the pharmacist was important in this case because it supported the medical team in having access to DM/Q and monitoring its efficacy and security. This case will help professionals review their central role in treating this complex and disabling condition.

Case presentation
An 86-year-old woman admitted in our geriatric inpatient unit exhibited frequent episodes of involuntary, uncontrolled, particularly disturbing outbursts of crying and, less frequently, uncontrolled episodes of laughing. She also had
episodes of wandering at night. The situation was becoming untenable and could not be managed by her husband any-
more. Past medical history was positive for hypertension,
osteoporosis, gait abnormality, nocturnal urinary inconti-
nence, and Alzheimer’s disease (AD) with related behavioral
problems. Her medications included amlodipine (2.5 mg
daily), venlafaxine (75 mg daily), quetiapine (25 mg at bed-
time), and calcium/vitamin D (500 mg/400 units daily).
Parkinsonism was present on physical examination.

The initial workup included biochemical and laboratory
investigation to exclude metabolic, inflammatory, hormo-
nal, and toxic causes for dementia. All results were within
normal limits. This patient had an obvious adverse impact
on activities of daily living and, as she had a progressive and
severe multi-domain cognitive decline, she could not per-
form an MMSE (Mini-Mental State Examination). Brain
computerized tomography (CT) scan performed 4 years ear-
lier showed mild cerebral atrophy and leukoaraiosis in the
white matter regions of the brain (Figure 1). An electromyo-
gram was performed to rule out motoneuron disease, which
was negative. Magnetic resonance imaging (MRI) revealed
non-specific subcortical signal abnormalities of the white
matter associated with subcortical ischemic changes and a
left-sided cerebellar lacuna (Figure 2). Brain positron emis-
tion tomography (PET) with fluoro-2-deoxy-d-glucose
(FDG) was in favor of a mixed neurodegenerative disorder,
showing an altered metabolic pattern suggestive of AD
dementia or/and dementia with Lewy bodies (DLB). DLB
could explain the parkinsonism symptoms observed in the
patient. She was seen by a psychiatrist who diagnosed dys-
regulation of affective expression without evidence of

significant depressive or anxious symptoms. Following
evaluation by a neurologist, PBA secondary to a mixed neu-
rodegenerative disorder was considered the likely diagno-
sis. Imaging with dopamine transporter agents would have
been helpful to obtain a more precise diagnosis, but it is not
available at our center.

Venlafaxine was stopped to try different medications.
Table 1 describes the medication trials received by the patient
during her hospitalization in order to reduce her crying and
laughing symptoms. DM/Q was determined to be the most
effective medication. A mild improvement was observed by
the husband following 3 days of treatment. After 1 week, the
effect was more apparent, as crying episodes were less fre-
quent and of shorter duration. After 2 weeks, the crying epi-
isodes were reduced by 50% and wandering at night was less
disturbing. At that point, the patient was discharged home
with DM/Q and then 1 year later moved to a nursing home,
where she died a few weeks after admission.

Discussion

The pathophysiology of PBA is not well established; the best
hypothesis remains a disruption of the cortico–pontine–cere-
bellar circuit, resulting in a lack of emotional control.1,6
Several neurotransmitters are implicated in PBA, mostly
serotonin and glutamate.1 This condition is associated with
different neurological disorders such as stroke, amyotrophic
lateral sclerosis (ALS), multiple sclerosis (MS), traumatic
brain injury (TBI), AD or Parkinson’s disease (PD).4 In one
study, among several neurological disorders, the mean prev-
alence of PBA was 36.7%, and TBI was the most prevalent
etiology at 52.4%.4 In our case, PBA was secondary to a
mixed neurodegenerative disorder (possibly AD or/and
DLB), which correlates with the scientific literature. Patients
affected by PBA have an increased risk of social and rela-
tionship problems as well as psychiatric symptoms.1,6 The
medical team initially considered relocating the patient to a
nursing home because her husband was overwhelmed by the
situation. Eventually, the DM/Q combination greatly helped
in reducing her symptoms and allowed her to return home.

The most recent diagnostic criteria for PBA published
by Miller et al.1 are listed in Table 2. The Center for
Neurologic Study–Lability Scale (CNS-LS) is also helpful
for PBA screening. Table 3 shows the self-report items of
the CNS-LS developed by Moore et al.5 Each item must be
evaluated on a scale of 1 to 5: 1 (never), 2 (rarely), 3 (occas-
ionally), 4 (frequently), and 5 (most of the time).7 The
CNS-LS is strictly validated for screening PBA in ALS and
MS.2 Therefore, using this scale for neurological disorders
other than ALS and MS, as was the case in our patient,
requires caution. The CNS-LS cutoff point to detect PBA is
13 or more for ALS and 17 or more for MS.2 The case
description and the neurologist evaluation confirmed that
our patient had the four essential criteria seen in Table 2 to
diagnose PBA.
Figure 2. MRI brain showing (a) nonspecific subcortical signal abnormalities of the white matter associated with subcortical ischemic changes and (b) a left-sided cerebellar lacuna.

Table 1. Medication trials during hospitalization.

| Medication          | Dosage                          | Effect                        | Discharge |
|---------------------|---------------------------------|-------------------------------|-----------|
| Crying and laughing|                                 |                               |           |
| Mirtazapine         | 30 mg daily                      | No effect                     | No        |
| Paroxetine          | 15 mg daily                      | No effect                     | No        |
| Fluoxetine          | 10 mg daily                      | No effect on PBA              | No        |
| Sertraline          | 50 mg daily                      | No effect                     | Yes       |
| DM/Q                | 20/10 mg daily × 1 week, then twice daily | Clinical global impression improved ≥50% at discharge | Yes       |
| Oxazepam            | 5 mg twice daily as needed       | Helping partially             | Yes       |
| Parkinsonism        |                                 |                               |           |
| Levodopa/carbidopa  | 50 mg twice daily                | Worsened behavior             | No        |

PBA: pseudobulbar affect; DM/Q: dextromethorphan/quinidine.

Table 2. Diagnostic criteria for PBA proposed by Miller et al.1

Essential criteria

Patient experiences episodes of involuntary or exaggerated emotional expression that result from a brain disorder, including episodes of laughing, crying, or related emotional displays.

Episodes represent a change in the patient’s usual emotional reactivity, are exaggerated or incongruent with the patient’s subjective emotional state, and are independent or in excess of the eliciting stimulus.

Episodes cause clinically significant distress or impairment in social or occupational functioning.

The symptoms cannot be attributed to another neurological or psychiatric disorder or to the effects of a substance.

Supportive criteria

Patient may experience accompanying autonomic changes (e.g. flushing of the face) and pseudobulbar signs (e.g. increased jaw jerk, exaggerated gag reflex, tongue weakness, dysarthria, and dysphagia).

Patients may exhibit a proneness to anger.

PBA: pseudobulbar affect.
Table 4. Differential diagnostic of PBA.1,6

| Psychiatric conditions          |     |
|--------------------------------|-----|
| Depression                     |     |
| Bipolar disorder               |     |
| Posttraumatic stress disorder  |     |

| Rare conditions                |     |
| Essential crying               |     |
| Witzelsucht                    |     |
| Epilepsy                       |     |
| Toxic effect of drugs          |     |
| Substance abuse                |     |
| Chemotherapy                   |     |
| Other                          |     |
| Euphoria in MS                 |     |

PBA: pseudobulbar affect; MS: multiple sclerosis.

Table 5. Double-blind studies in the treatment of PBA.2

| Medication | Dose                                                                 |
|------------|----------------------------------------------------------------------|
| Amitriptyline | Mean dosage of 57.8 mg daily, but the maximum dosage used is 75 mg daily |
| Nortriptyline | 20 mg daily × 1 week, 50 mg daily × 2 weeks, 70 mg daily × 1 week, then 100 mg daily |
| Citalopram | ☀️65 years old: 20 mg daily < 65 years old: 10 mg daily |
| Fluoxetine | 20 mg daily |
| Sertraline | 50 mg daily but may increase to 100 mg daily after 4 weeks at 50 mg daily |
| DM/Q      | • FDA: 20/10 mg daily × 1 week, then twice daily³ <br>• EU: Same as FDA, but if the response is not achieved after 3 weeks at 20/10 mg twice daily, then may increase to 30/10 mg twice daily⁹ |

DM/Q: dextromethorphan/quinidine; FDA: Food and Drug Administration; EU: European Union.

Table 3. Self-report items of the CNS-LS developed by Moore et al.7

| Laughter subscale                                                                 |
|-----------------------------------------------------------------------------------|
| I find that even when I try to control my laughter I am often unable to do so.    |
| I find that I am easily overcome by laughter.                                     |
| There are times when I won’t be thinking of anything happy or funny at all, but then I'll suddenly be overcome by funny or happy thoughts. |
| Others have told me that I seem to become amused very easily or that I seem to become amused about things that really aren’t funny. |

| Tearfulness subscale                                                                 |
|-------------------------------------------------------------------------------------|
| I find myself crying very easily.                                                   |
| There are times when I feel fine 1 min, and then I'll become tearful the next over something small or for no reason at all. |
| I find that even when I try to control my crying I am often unable to do so.        |

CNS-LS: Center for Neurologic Study–Lability Scale.

Treatement of PBA is described in Table 5. Published studies assessing the benefits of antidepressants in PBA are small, difficult to compare, and included patients where the underlying disorder was usually stroke.1 Response to antidepressants in PBA seems faster and occurs at lower doses than in psychiatric conditions.2 The only approved treatment of PBA by the Food and Drug Administration (FDA) and the European Union (EU) is DM/Q. The active drug dextromethorphan is an N-methyl-D-aspartate receptor antagonist and a sigma-1 receptor agonist.3,9 Quinidine is only necessary to increase the concentration of dextromethorphan by inhibiting the cytochrome P450 2D6 (CYP2D6).3,9 DM/Q was first studied in MS and ALS,2,3,9 but recently in the PRISM II trial,8 DM/Q was effective in patients with dementia and PBA. Our patient could be compared to the PRISM II study as their population included different types of dementia. There is no head-to-head study comparing antidepressants and DM/Q, but the clinical experience of one clinician seems to suggest that DM/Q could be associated with a better response in PBA.2 We could argue the same with our case, as the outcome was considerably better with DM/Q compared to several antidepressants. Her crying episodes improved significantly and rapidly after the initiation of DM/Q, so we did not need to monitor the effectiveness of the medication with the evolution of CNS-LS score.

The most frequent adverse drug reactions from short-term trial of DM/Q are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, elevated gamma-glutamyltransferase, and flatulence.3 An electrocardiogram (ECG) is recommended after the first dose of DM/Q to monitor the QT interval,2 even though, according to the European Medicines Agency, there is a low risk of QT prolongation for patients without cardiac disease.9 The QT interval of our patient was normal after the first dose of DM/Q. Recognizing quinidine is a CYP2D6 inhibitor, drug
interactions must be considered, especially if the interaction involves a drug that prolongs QT interval. Moreover, quinidine is metabolized by CYP3A4; CYP3A4 inducers or CYP3A4 inhibitors must therefore be avoided. CYP3A4 inhibitors could increase the risk of QT prolongation. The use of an antidepressant with DM/Q should be approached with caution due to a possible risk of pharmacokinetic or pharmacodynamic interactions (QT prolongation, serotonin syndrome), depending on the antidepressant. Finally, quinidine is a P-glycoprotein inhibitor. The sertraline could have been reassessed for our patient when we noticed the effectiveness of DM/Q, but the medical team decided to keep it as they did not want to risk any deterioration. Indeed, the goal of care was to provide comfort, which was much improved compared to her state upon admission. We considered the risk of interaction low, and the combination was well tolerated.

Since DM/Q is not available in Canada, we had to find an alternative for our patient. First, we used the expertise of a pharmaceutical laboratory to make compounded 10 mg quinidine capsules. As we did not know whether the patient would need 20 or 30 mg of dextromethorphan, we determined that a dextromethorphan cough syrup was an easy available option to facilitate the titration. However, we stopped at 20 mg, as it achieved a good effectiveness. Interestingly, we found two case reports with positive response for PBA in which DM/Q was changed to dextromethorphan cough syrup plus fluoxetine, considering fluoxetine is also a CYP2D6 inhibitor. This treatment combination was not considered for our patient as she had presented akathisia induced by fluoxetine.

Conclusion

PBA is a common finding in neurological disorders and it must not be confused with a psychiatric condition. Good patient care is essential to minimize the disruptive consequences of PBA on the patient and his or her family. A subset of patients will not respond to antidepressants for treating PBA; in this case, DM/Q is a good alternative. This case report could help pharmacists and other professionals considering compounded quinidine capsules and dextromethorphan cough syrup as an alternative to the marketed DM/Q combination when it is not available. The pharmacist can play an important role in supporting the medical team in the treatment and monitoring of patients with this condition.

Acknowledgements

The authors thank Audrey Attia for her support with the literature search, Theresa Feeser for editing the manuscript, and Dr David Landry for selecting CT/MRI images. All of the authors approved the final version and agreed to be accountable for all aspects of the work.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Ethical approval

Our institution does not require ethical approval for reporting individual cases or case series.

Informed consent

Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.

ORCID iD

Yannick Villeneuve https://orcid.org/0000-0001-9186-774X

References

1. Miller A, Pratt H and Schiffer RB. Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments. Expert Rev Neurother 2011; 11(7): 1077–1088.
2. Pioro EP. Current concepts in the pharmacotherapy of pseudobulbar affect. Drugs 2011; 71(9): 1193–1207.
3. Cruz MP. Nuedexta for the treatment of pseudobulbar affect: a condition of involuntary crying or laughing. P T 2013; 38(6): 325–328.
4. Brooks BR, Crumpacker D, Fellus J, et al. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions. PLOS ONE 2013; 8(8): e72232.
5. Arciniegas DB, Lauterbach EC, Anderson KE, et al. The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr 2005; 10(S1): 34–44.
6. Sauve WM. Recognizing and treating pseudobulbar affect. CNS Spectr 2016; 21(S1): 1–14; quiz 15–16.
7. Moore SR, Gresham LS, Bromberg MB, et al. A self report measure of affective lability. J Neurol Neurosurg Psychiatry 1997; 63(1): 89–93.
8. Woody RS, D’Amico S, Cutler AJ, et al. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. CNS Spectr 2016; 21(6): 450–459.
9. Yang LP and Deeks ED. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Drugs 2015; 75(1): 83–90.
10. Schoedel KA, Morrow SA and Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatr Dis Treat 2014; 10: 1161–1174.
11. Butler MI, Williams D and Cotter DR. Cough suppressant and fluoxetine in the treatment of pseudobulbar affect: a case report. J Clin Psychopharmacol 2016; 36(5): 525–526.
12. McGrane I, VandenBerg A and Munjal R. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. Ann Pharmacother 2017; 51(11): 1035–1036.